The GeneXpert diagnostic testing technology from the US corporation Cepheid, and its parent company Danaher, has revolutionised rapid, accurate diagnosis of tuberculosis (TB) and other diseases, since entering the market in 2010. Yet, due to the high cost of the GeneXpert test cartridges, many countries are not able to scale up testing for all people who need lifesaving diagnosis and subsequent treatment.
Ahead of Gavi's Board Meeting 30 July 2020, over 175 civil society organisations and individuals, including MSF Access Campaign, wrote an open letter to the Board demanding better representation of civil society and communities in the ...
This analysis of Gavi's Advance Market Commitment (AMC) for Pneumococcal Conjugate Vaccines (PCVs) takes a critical look at issues with the AMC model, which is being replicated for other vaccines.
12 Sep 2019: At Global Vaccination Summit being held in Brussels, Belgium today, MSF writes an open letter to Gavi, the Vaccine Alliance, vaccine manufacturers and donor governments to take urgent measures to make lifesaving vaccines ...
Vaccines against pneumococcal disease and human papillomavirus are two important new tools for saving lives and protecting health. They’re also under patent - and expensive. Our report, “A Fair Shot for Vaccine Affordability,” finds ...